Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside
Despite recent advances in high-risk neuroblastoma therapy, the prognosis for patients remains poor. In addition, many patients suffer from complications related to available therapies that are highly detrimental to their quality of life. New treatment modalities are, thus, urgently needed to furthe...
Na minha lista:
| Principais autores: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2018-01-01
|
| coleção: | OncoImmunology |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/2162402X.2017.1373232 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|